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Abstract: Background: Pneumonia is the leading cause of death among infectious diseases in developed countries. 
However, the severity of pneumonia requiring hospitalization often makes the initial diagnosis difficult because of an 
equivocal clinical picture or interpretation of the chest film. The objective of the present study was to assess the 
usefulness of the plasma levels of mid-regional proadrenomedullin (MR-proADM) and mid-regional proatrial natriuretic 
peptide (MR-proANP) in differentiating pneumonia from other lower respiratory tract infections (LRTIs). 
Methods: A retrospective study was conducted. The plasma levels of MR-proADM and MR-proANP were measured in 85 
patients hospitalized for LRTIs, 56 of whom with diagnosis of pneumonia and 29 with other LRTIs. 
Results: The patients with pneumonia had increased MR-proADM levels (median 1.46 nmol/L [IQR 25-75, 0.82-2.02 
nmol/L]) compared with the patients with other LRTIs (median 0.88 nmol/mL [0.71-1.39 nmol/L]) (p= 0.04). However, 
the MR-proANP levels did not show differences between the groups. The optimal threshold of MR-proADM to predict 
pneumonia was 1.5 nmol/L, which yielded a sensitivity of 51.7% (95% CI, 38.0-65.3), a 79.3% specificity (95% CI, 60.3-
92.0), and an odds ratio of 6.64 (95% CI, 1.32-32.85). The combination of this parameter with C-reactive protein in an 
“and” rule increased the specificity for detecting pneumonia significantly. 
Conclusion: MR-proADM levels (but not MR-proANP levels) are increased in patients with pneumonia although its 
discriminatory power is moderate. 
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INTRODUCTION 
 Pneumonia is the sixth leading cause of death in general 
and the first among all infectious diseases in developed 
countries [1-3]. However, discriminating pneumonia from 
other chest infections where antibiotics are not required (i.e. 
acute bronchitis), particularly in its early stages, is 
sometimes difficult. In older patients, the clinical 
presentation is unclear, and interpreting chest radiographs 
can be difficult in patients with severe disease or previous 
pulmonary disease [4, 5]. 
 The search for biomarkers to serve as diagnostic tools for 
clinicians has not yet produced a reliable tool. One 
biomarker of interest is mid-regional proadrenomedullin 
(MR-proADM), a more stable mid-region fragment of the 
parent precursor adrenomedullin [6]. Adrenomedullin is a 
peptide that is produced by multiple tissues types; it has 
pluripotent functions, including vasodilatory, antimicrobial, 
and anti-inflammatory activities [7]. In animal models of 
 
 
*Address correspondence to this author at the Department of Internal 
Medicine, Arnau de Vilanova University Hospital, IRBLLEIDA. C/ Rovira 
Roure 80. 25198 Lleida, Spain; Tel: +34 973 248100;  
Fax: +34 973 288754.; E-mail: agustinruiz@saludalia.com 
sepsis, exogenous adrenomedullin reduced acute lung injury, 
vascular permeability, and death [8-10]. On the other hand, 
mid-regional proatrial natriuretic peptide (MR-proANP) is a 
more stable mid-region fragment precursor of atrial 
natriuretic peptide, and the stimuli for its production most 
likely include proinflammatory factors and hypoxia. Its 
expression has been found in many tissues, but it is mainly 
produced in the atrium of the heart [11-12]. In previous 
studies, MR-proADM and MR-proANP levels have 
correlated with severity of pneumonia and death [13-17]. 
However, data on the diagnostic usefulness of these 
biomarkers is lacking in the literature. 
 Therefore, we examined the MR-proADM and MR-
proANP levels in a cohort of patients with lower respiratory 
tract infections (LRTIs) requiring hospitalization. We sought 
to describe the pattern of the initial biomarkers in pneumonia 
and other LRTIs, and to assess the potential diagnostic role 
in pneumonia. 
MATERIALS AND METHODS 
Study Sample 
 Since 2010, consecutive patients over age 18 with LRTIs 
requiring hospital admission were asked to provide 
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additional blood samples for investigation. The study 
protocol was approved by the local ethical committee, and 
all of the participants provided written informed consent for 
the collection and storage of blood upon admission. Plasma 
was obtained by centrifugation and stored frozen at -80ºC. 
For the present study, 85 plasma samples were randomly 
selected. 
Diagnostic Criteria 
 LRTI was defined by the presence of at least one 
respiratory symptom (e.g., cough, sputum production, 
dyspnea, tachypnea, pleuritic pain) plus at least one finding 
during auscultation (i.e., rales) or one sign of infection 
(temperature >38.0°C, shivering, leukocyte count >10 or <4 
x109 cells) regardless of antibiotic use. For CAP, a new 
infiltrate on the chest radiograph was also required. COPD 
was defined by post-bronchodilator spirometric criteria 
according to the Global initiative for Chronic Obstructive 
Lung Disease (GOLD)-guidelines as a FEV1/FVC ratio < 
70%. Acute bronchitis was defined as a LRTI in the absence 
of an underlying lung disease or focal chest signs and 
infiltrates on chest X-rays [18, 19]. A panel of three 
specialists had been previously reviewed chest X-rays from 
the patient population. Panel consensus in classifying LRTI 
was required for study inclusion. 
 The exclusion criteria were: 1) severe immunosuppres-
sion (HIV infection or severe haematological diseases); 2) 
immunosuppressive therapy (prednisone or an equivalent 
dose of 20 mg daily for 2 weeks or any immunosuppressive 
regimen (azathioprine, cyclosporine, cyclophosphamide 
and/or other immunosuppressant drugs); 3) leukopenia 
(<1,000 leukocytes per mm3) or neutropenia (< 500 
neutrophils per mm3) and/or chemotherapy in the previous 
year; 4) pulmonary abscess (radiological cavitation), 
aspiration pneumonia and obstructive pneumonia; 5) 
possible nosocomial origin (30 days from hospital 
discharge); and 6) known active neoplasm. 
Data and Severity Assessment 
 The patients’ clinical parameters were included in an 
electronic database. Comorbidities were documented and 
defined as the presence of one or more of the following: 
congestive heart failure, chronic obstructive pulmonary disease, 
chronic renal disease, chronic liver disease, cerebrovascular 
disease, malignancy, or diabetes mellitus. The microbiological 
work-up in the patients with pneumonia included sputum and/or 
bronchoalveolar lavage fluid samples for the Gram stain and 
culture, a urine sample for detecting Legionella pneumophila 
and Streptococcus pneumoniae antigens, and serological testing 
for Mycoplasma pneumoniae and Chlamydophila pneumoniae. 
The detection of respiratory pathogens was performed 
according to standard methods. In patients with severe 
exacerbations of COPD, a sputum sample was collected for the 
Gram stain and sputum culture. No microbiological tests were 
performed in the patients with acute bronchitis. 
 The severity assessment was made with the CURB-65 
score and performed upon admission to the emergency 
department. The CURB-65 score consists of five variables: 
confusion, urea, respiratory rate ≥ 30 breaths/min, blood 
pressure (systolic) < 90 mm Hg or diastolic ≤ 60 mmHg, and 
age ≥ 65 years [20]. One point is given for each parameter 
present, which results in CURB-65 scores of 0-5. The 
criteria for ICU admission were based on the American 
Thoracic Society (ATS) guidelines [21]. In brief, ICU 
admission was considered in patients with severe CAP, 
which was defined as the presence of one of two major 
criteria (the need for mechanical ventilation or septic shock), 
the presence of two of three minor criteria (systolic blood 
pressure <90 mmHg, multilobar disease, or PaO2/FIO2ratio 
<250) or more than two CURB points. For COPD patients, 
the ICU criteria included severe acidosis or respiratory 
failure (pH <7.25, pO2 < 40 mmHg), no response to initial 
treatment in the emergency department or worsening mental 
status (confusion, coma) despite adequate therapy [19]. 
Laboratory Measurements 
 Both MR-proADM and MR-proANP were measured in 
duplicated in stored EDTA plasma samples by the TRACE® 
technology, as previously described [22, 23]. The procedure 
was fully automated in a KRYPTOR Compact analyzer 
(B.R.A.H.M.S. AG, Hennigsdorf, Germany). The other 
biochemical determinations were routinely performed as part 
of the admission study using conventional laboratory 
methods. 
Statistical Analysis 
 The categorical variables were expressed as counts 
(percentages), and the continuous variables were expressed 
as medians and interquartile ranges (IQR), as appropriate. 
The χ2 and Fisher’s exact tests were used, as appropriate, to 
compare the qualitative variables. In the case of quantitative 
variables, the Mann-Whitney U-test was used. 
 To assess the accuracy of the biomarkers for predicting 
the presence of pneumonia, we generated receiver operating 
characteristic curves and determined the area under the curve 
(AUC) and its 95% confidence interval (95% CI). For each 
ROC curve, a cut-off point was determined as the value of 
the biomarker that maximised the sum of the sensitivity and 
specificity for diagnosing pneumonia. Pairwise comparisons 
of the AUC were conducted, following the Hanley and 
McNeil procedure. To adjust for confounders, a logistic 
regression model estimated the simultaneous impact of CRP 
and MR-proADM, along with significant variables in the 
univariate analysis predicting pneumonia. Associations were 
considered to be statistically significant if the p-value was 
<0.05. The statistical software packages used were SPSS 
15.0 (SPSS Inc., Chicago, IL, USA) and MedCalc version 
12.3.0 (MedCalc, Mariakerke, Belgium). 
RESULTS 
Baseline Characteristics 
 A total of 85 patients who were hospitalized for LRTIs were 
recruited; 56 were diagnosed with pneumonia and 29 with other 
LRTIs (13 with acute exacerbation of chronic obstructive 
pulmonary disease and 16 with acute bronchitis). The mean 
patient age was 71.0 years (range 20-96); 69.4% were males, 
and 62.4% had comorbidities. Of the participants, 8.2% arrived 
from nursing home facilities. The patients with pneumonia had 
a median CURB65 score of 2.5. During the follow-up, 3 (3.5%) 
patients were transferred to the ICU, and 7 (8.2%) died (6 with 
pneumonia and 1 with other LRTIs). The mean in-patient stay 
was 8.4 days (range 2-41). 
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 Microbiological work-up were performed in patients with 
pneumonia or with severe exacerbations of COPD. A final 
etiological diagnosis was established in 29 (42.0%) patients. 
The microorganisms identified were: Streptococcus pneu-
moniae (19), Chlamydophila pneumoniae (6), Legionella 
pneumophila, Staphylococcus aureus, Escherichia coli, and 
Aspergillus fumigatus (1 each). 
Data Analysis 
 A comparison of the clinical, analytical and follow-up 
data between the groups is shown in Table 1. In a univariate 
analysis, 5 variables were different between the patients with 
pneumonia and those with other LRTIs: acute onset of 
symptoms (48% vs 14%), heart rate (100 vs 89 beats/min), 
the presence of rales (64% vs 14%), CRP (222 vs 102 mg/L) 
and MR-proADM (1.46 vs 0.88 nmol/L). However, in the 
multivariate analysis, the presence of rales, CRP and MR-
proADM maintained significant differences only. 
 Fig. (1) shows MR-proANP levels in the study 
population. The patients with pneumonia had similar MR-
proANP levels (median 233 pmol/L [IQR 25-75, 115-398 
pmol/L]) compared with those with other LRTIs (median 
259 pmol/L [110-399 pmol/L]) (p=0.88). Conversely, the 
patients with pneumonia had increased MR-proADM levels 
(median 1.46 nmol/L [IQR 25-75, 0.82-2.02 nmol/mL]) 
compared with the patients with other LRTIs (median 0.88 
nmol/L [0.71-1.39 nmol/L]) (p=0.04) (Fig. 2). 
 The AUC for MR-proADM to discriminate between the 
patients with pneumonia and other LRTIs was 0.65 (95% CI, 
0.53-0.76), which was not inferior to the result obtained for 
CRP (0.78 [95% CI, 0.67-0,86], p=0.11). The optimal threshold 
(minimal false negative and false positive results) of MR-
proADM to predict pneumonia was 1.5 nmol/L, which yielded a 
sensitivity of 51.7% (95% CI, 38.0-65.3), a 79.3% specificity 
(95% CI, 60.3-92.0). As Table 2 shows, combining MR-
proADM with CRP in an “and” rule increased the specificity to 
96% (95% CI, 82-99) and the likelihood ratio positive to 9.2 
(95% CI, 1.3-65.1) for detecting pneumonia. 
DISCUSSION 
 In the present study, MR-proADM levels but not MR-
pro-ANP levels were found to be increased in patients with 
pneumonia compared with other LRTIs. 
Table 1. Comparison between the patients with pneumonia and those with other lower respiratory tract infections (LRTIs). 
 
 Pneumonia N=56 
Other LRTIs 
N=29 p Value p Value* 
Clinical findings 
Days of illness 3 (2-5) 5 (3-7) 0.14  
Previous antibiotic treatment 14 (25) 11 (38) 0.21  
Acute onset 27 (48) 4 (14) 0.00 0.39 
Chills 24 (43) 7 (24) 0.08  
Cough 46 (82) 24 (82) 0.94  
Sputum 26 (46) 14 (48) 0.87  
Pleuritic chest pain 20(36) 6 (21) 0.15  
Physical findings 
Confusion 10 (18) 1(3) 0.05  
Body temperature (ºC) 37.3 (36.4-38) 37 (36.6-37.7) 0.27  
Systolic blood pressure (mmHg) 118 (91-139) 127 (108-142) 0.20  
Heart rate (beats/min) 100 (80-111) 89 (77-101) 0.03 0.08 
Respiratory rate (breaths/min) 28 (20-36) 24 (24-29) 0.97  
Rales 36 (64) 4 (14) 0.00 0.01 
Laboratory 
WCC (white cell count) (x109) 12.3 (7.7-17.3) 11.5 (7.7-14.4) 0.37  
Haematocrit % 41 (36-45) 41 (35-47) 0.89  
Urea mg/dL 56 (40-81) 37 (28-76) 0.05  
Sodium mmol/L 138 (133-140) 138 (136-140) 0.77  
pO2 (mm Hg) 62 (54-79) 64 (53-75) 0.86  
C-reactive protein (mg/L) 222 (149-278) 102 (59-152) 0.00 0.01 
MR-proADM (nmol/L) 1.46 (0.82-2.02) 0.88 (0.71-1.39) 0.04 0.03 
MR-proANP (pmol/L) 233 (115-398) 259 (110-399) 0.88  
The data are expressed as the median (IQR) or N (%). * Multivariate analysis. 
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Fig. (1). Box plots of the MR-proANP plasma levels in the study 
population. The patients with pneumonia had similar MR-proANP 
levels (median 233 pmol/L [IQR 25-75, 115-398 pmol/L]) 
compared with those with other LRTIs (median 259 pmol/L [110-
399 pmol/L]) (p=0.88). The Box plots represent the 25th and 75th 
percentiles, with the internal horizontal lines showing the median. 
T-shaped bars represent the 10th and 90th percentiles. IQR, 
interquartile range; MR-proANP, mid-regional proatrial natriuretic 
peptide. 
 
Fig. (2). Box plots of the MR-proADM plasma levels in the study 
population. The patients with pneumonia had increased MR-
proADM levels (median 1.46 nmol/L [IQR 25-75, 0.82-2.02 
nmol/mL]) compared with those with other LRTIs (median 0.88 
nmol/L [0.71-1.39 nmol/L]) (p=0.04). The MR-proADM units are 
expressed as natural logarithm. The box plots represent the 25th and 
75th percentiles, with the internal horizontal lines showing the 
median. T-shaped bars represent the 10th and 90th percentiles. IQR, 
interquartile range; MR-proADM, mid-regional proadrenomedullin. 
 The diagnosis of pneumonia is sometimes difficult in 
clinical practice. In older patients, the clinical presentation is 
unclear, and the accuracy of chest radiography, which 
remains the reference technique for diagnosing pneumonia, 
is 65% compared with a CT scan [24]. In addition, the search 
of biomarkers that could help in managing infections has 
produced conflicting results [25]. 
Table 2. MR-proADM characteristics alone or combined 
with C-reactive protein to predict pneumonia. 
 
Serum Markers Sensitivity Specificity LR+ LR- 
MR-proADM 
>1.5 nmol/L 
51.7 
(38.0 - 65.3) 
79.3 
(60.3 - 92.0) 
2.5 
(1.2 - 5.3) 
0.6 
(0.4 - 0.8) 
CRP 
>150 mg/L 
75.4 
(61.7 - 86.2) 
77.2 
(54.6 - 92.2) 
3.3 
(1.5 - 7.3) 
0.3 
(0.2 - 0.5) 
MR-proADM 
>1.5 nmol/L and 
CRP >150 mg/L 
34.0 
(22.7 – 47.4) 
96.3 
(81.7 – 99.3) 
9.2 
(1.3 - 65.1) 
0.6 
(0.5 - 0.8) 
The data are presented as % (95% CI). LR+: likelihood ratio positive; LR-: likelihood 
ratio negative. 
 
 In a study of 151 patients with systemic inflammatory 
response syndrome, the AUC for detecting a bacterial cause 
was 0.72 for procalcitonin (PCT), 0.74 for neutrophil count, 
and 0.81 for CRP [26]. In a study of 545 patients with LRTIs 
(373 with CAP), the AUCs of a clinical model, PCT and 
CRP were 0.79, 0.76 and 0.88, respectively, to detect 
patients with pneumonia [27]. 
 Both, MR-proANP and MR-proADM have been recently 
incorporated into the race of biomarkers primarily by adding 
prognostic information. Thus, in a study of 300 patients with 
pneumonia, the MR-proANP levels were significantly higher 
in the patients with high PSI risk class (IV-V) than in those 
with low PSI risk class (I-III) [13]. In a multicentre 
prospective study of 1,653 patients with pneumonia, MR-
proADM had a higher AUC for 30-day mortality than PCT 
(0.76 vs 0.65, respectively) [14]. In the multicentre ProHOSP 
study [15], the authors compared the prognostic accuracy of 
several biomarkers with the PSI and CURB65 clinical scores 
in 1,359 patients with LRTIs. The discriminatory power of 
biomarkers for predicting death ranged from an AUC of 0.60 
for PCT to 0.76 for MR-proADM and 0.79 for MR-proANP. 
The CURB65 and PSI score had an AUC of 0.74 and 0.84, 
respectively. In the multicentre CAPNETZ study [16], the 
authors compared the prognostic accuracy of several 
biomarkers with the PSI and CRB65 clinical scores in 728 
patients with CAP. The AUC of MR-proADM for 28-day 
mortality (0.85) was superior to those of MR-proANP (0.81) 
and CRB-65 (0.72) for predicting mortality. Recently, MR-
proADM has shown a better discriminatory power than PSI 
score in identifying risk of death among CAP patients with 
PSI class IV and V (0.81 vs 0.66, respectively) [28]. In 
addition, the utility of MR-proANP or MR-proADM have 
also been analysed to detecting the aetiology, the presence of 
bacteraemia, the risk of developing complications, or the 
need for ICU admission in patients with LRTIs [17, 29-31]. 
 To the best of our knowledge, this is the first study 
analysing the diagnostic performance of MR-proANP and 
MR-proADM in an LRTI population. Our results supported 
the notion that high MR-proADM levels are found in 
patients with pneumonia compared with other LRTIs. At cut-
off levels of 1.5 nmol/L, the discriminatory power of MR-
proADM was moderate (sensitivity and specificity of 
approximately 52% and 80%, respectively). However, the 
combination of MR-proADM with CRP (at cut-off levels of 
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150 mg/L) in an “or/and” rule, significantly improved the 
operating characteristics. Indeed, the presence of any of both 
biomarkers showed a sensitivity of 86%, whereas the 
presence of both biomarkers increased the specificity to 96% 
and the likelihood ratio positive to 9.2. By this rule, 
approximately 15% of patients with pneumonia were missed. 
However, the levels of MR-proANP did not differ between 
the groups. The fact that MR-proADM seems to be superior 
to MR-proANP might be explained by the multiple 
biological functions of adrenomedullin. Indeed, 
adrenomedullin is one of the most potent vasodilation agents 
with immune modulating, metabolic and bactericidal 
properties. In contrast, natriuretic peptides such as ANP 
correlate with the presence of heart of renal failure, which 
may be present only in the subgroup of patients with LRTIs 
and poor prognoses [6-12]. 
 The present study has some limitations. First, the design 
was retrospective, and the effects of sample storage on the 
measurements have not been evaluated. Second, the 
population evaluated included adult patients with LRTIs who 
required hospital care; therefore, it may not be possible to 
extrapolate our conclusions to populations with mild LRTIs. 
Finally, immunosuppressed patients were excluded from the 
analysis, and this patient group has difficult diagnoses that 
could benefit from the use of biomarkers. 
 In our opinion, further studies with larger samples are 
needed to analyze the usefulness of MR-proADM testing 
alone or in combination with other biomarkers in the 
management of respiratory infections. 
CONCLUSION 
 Among hospitalized patients with LRTIs, MR-proADM 
levels are increased in patients with pneumonia. The optimal 
threshold of MR-proADM to predict pneumonia was 1.5 
nmol/L, which yielded a specificity of 79.3%. MR-proANP 
levels did not show differences between groups. 
ABBREVIATIONS 
CAP = Community-acquired pneumonia 
LRTI = Lower respiratory tract infection 
MR-proADM = Mid-regional proadrenomedullin 
MR-proANP = Mid-regional proatrial natriuretic peptide 
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